OnCo
drugsProductNot mapped hereapproved

Arsenic trioxide

An ancient poison turned cure: with retinoic acid it cures more than 95% of acute promyelocytic leukaemia without conventional chemotherapy.

Developed from traditional Chinese medicine in Harbin (1990s); approved 2000 for relapsed APL and 2018 first line with tretinoin after APL0406 (Lo-Coco, NEJM 2013) showed ATRA-ATO superior to ATRA-chemotherapy in standard-risk APL. Toxicities: differentiation syndrome, QT prolongation, hepatotoxicity. Oral arsenic (Realgar-Indigo naturalis) is used in China.

Loading structure…
|
Arsenic trioxide · 2D coordinates (no PubChem conformer)
PubChem
Modality
Inorganic arsenical (differentiation agent)
Mechanism
Binds PML moiety of PML-RARA, inducing SUMOylation and degradation of the fusion oncoprotein; triggers differentiation and apoptosis of APL blasts.
Brand / code
Trisenox
Medicare
Part B (clinician-administered)

Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic; daily infusions in the clinic during consolidation.

Commercial insurance
covered on label

Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.

Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.

NICE recommendedNICE TA526 · 2018SMC: accepted
Appraised for
Acute promyelocytic leukaemia (untreated low-to-intermediate risk with ATRA, and relapsed)
NHS England
Routinely funded for the appraised indication (or via managed access)

Sources: NICE TA526 · SMC advice: arsenic trioxide. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.

Regulatory

3top

Approvals

RegionYearIndication
US2000Relapsed/refractory APL
US2018Newly diagnosed low-risk APL with tretinoin
EU2002APL

Trials

top

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Arsenic trioxide
intervention: Arsenic trioxide
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Arsenic trioxide" OR ABSTRACT:"Arsenic trioxide" OR TITLE:"Trisenox" OR ABSTRACT:"Trisenox") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Arsenic trioxide, not a curated reading list.

Connected

5top